2026 AHA Scientific Sessions: Achievement Report and Academic Exchange of SungenBiomed’s First-in-Class Myocardial-Infarction Antibody SGC001

Source: Hotgen Biotech
Date: 2026-11-16
Back to List

From November 6 to 9, 2026, AHA Scientific Sessions 2026 — the world’s largest and most academically influential annual meeting in the cardiovascular field — was held in Chicago, USA. Sungen Biomed which is a subsidiary of Hotgen Biotech brought Phase Ib clinical data of the independently developed first-in-class anti-S100A8/A9 monoclonal antibody SGC001 to the conference’s "Moderated Digital Poster" session, showcasing China’s development of originally innovative medicines for myocardial protection in acute ST-segment elevation myocardial infarction (STEMI) population.

30981542_1794795875.jpg
At 15:15–15:20 local time on November 8, Dr. Isabelle Ling Meng, Scientific Advisor of Sungen Biomed, delivered a report on behalf of the research team and all collaborators in Clinical Science Zone 2, under the title “Safety, Tolerability, Pharmacokinetics, and Efficacy of SGC001 in Chinese Patients with Acute STEMI: A Phase Ib Dose-Escalation Study” (poster number MDP1809). The Moderated Digital Poster session is one of the most anticipated sessions of AHA, requiring authors to deliver a timed oral presentation on site while responding to commentary and questions from international peers. This recognition represents the international academic community’s strong endorsement of the study design and development value, and provides Sungen Biomed a valuable opportunity for in-depth communication with leading cardiovascular experts worldwide.

SGC001 is a first-in-class monoclonal antibody targeting S100A8/A9 that Sungen Biomed  independently developed, addressing the unmet clinical need in reperfusion injury after acute STEMI. The Phase Ib study presented at AHA preliminarily confirmed the drug’s favorable safety and tolerability and revealed encouraging exploratory efficacy signals, providing strong support for subsequent development.

• Outstanding safety profile: SGC001 demonstrated favorable safety and tolerability across the low-, medium- and high-dose groups. No grade 3 or higher treatment-emergent adverse events (TEAEs) occurred, no serious adverse events (SAEs) were reported, and no patient discontinued the treatment because of adverse events.

• Dose-proportional PK/PD: Exposure to SGC001 increased with dose. Compared with the placebo and low-dose groups, the medium- and high-dose groups showed more pronounced reductions in high-sensitivity cardiac troponin I (hsTnI) and high-sensitivity C-reactive protein (hs-CRP), suggesting a potential exposure–response relationship.

• Cardiac magnetic resonance (CMR) revealed a positive efficacy trend: CMR assessment showed that SGC001 induced a marked reduction in myocardial infarct size, with the median infarct size reduced by 20.5% and 38.1% in the medium- and high-dose groups vs placebo, respectively. In improving microvascular obstruction (MVO), all three SGC001 treatment groups outperformed the placebo group.

After PCI revascularization in patients with acute myocardial infarction, ischemia–reperfusion injury remains an acute clinical challenge, readily aggravating myocardial damage and microvascular dysfunction and increasing the long-term risk of heart failure. Leveraging its differentiated innovative mechanism, SGC001 is expected to open a new therapeutic approach for these patients. The Phase II clinical study of this program is currently ongoing in China. Sungen Biomed will continue to deepen its original cardiovascular research, steadily advance pipeline development and keep delivering China -developed biopharmaceutical products.

share